sexta-feira, 13 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· December 28, 2025

GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy

View original at finance.yahoo.com
GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy On Jan. 4, 2023, GE HealthCare Technologies (No…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • As a standalone company, GE HealthCare can make decisions faster with better focus and less noise

    80% confidence
  • Med tech is an American gem with 70%+ of products made in the United States and majority of IP originating there

    80% confidence
  • Authenticity and direct communication are critical for CEOs in today's world with younger employee base and social media

    80% confidence
  • GE gave employees bold assignments at a very young age and had a tough but fair culture under Jack Welch

    80% confidence
  • R&D investment doubled from $750-800 million in 2018 to over $1.4 billion currently

    80% confidence
  • Innovation requires a 3 to 5 year cycle in the medical technology business

    80% confidence
  • Larry Culp characterized himself as a down-to-earth, focused, and intentional leader

    80% confidence
  • GE HealthCare reduced China imports from 75% to now making 85-90% of products locally for the China market

    80% confidence
  • China will eventually become the largest healthcare market with 1.4 billion people

    80% confidence
  • GE HealthCare stock is up almost 50% since IPO on January 4, 2023

    80% confidence
  • Harmony between China and the U.S. is beneficial for the world and necessary for GE HealthCare to reach full potential

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,995
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,995 factos verificados com a fonte5,577 documentos-fonte arquivados
Consulte estes dados → isubstrate.com
GE HealthCare CEO Peter Arduini is forging a new chapter for the $20 billion-a-year business while drawing on Jack Welch’s legacy — Source | Via News | pt.VIA.NEWS